Mouse Fc gamma RIII / CD16 Protein, His Tag (SPR & BLI & MALS verified)
分子別名(Synonym)
FCGR3
表達區(qū)間及表達系統(tǒng)(Source)
Mouse CD16, His Tag (CDA-M52H8) is expressed from human 293 cells (HEK293). It contains AA Leu 32 - Thr 215 (Accession # Q5D5I8).
Predicted N-terminus: Leu 32
蛋白結構(Molecular Characterization)
![1.jpg 1.jpg](/SupplyImg1/2025-01-20/6387296737565733977885643.jpg)
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 23.0 kDa. The protein migrates as 36-45 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
內(nèi)毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method.
純度(Purity)
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
![2.jpg 2.jpg](/SupplyImg1/2025-01-20/6387296738348918193793878.jpg)
![3.jpg 3.jpg](/SupplyImg1/2025-01-20/6387296738586434711634969.jpg)
背景(Background)
CD16是一種低親和力Fc受體,已被鑒定為Fc受體FcγRIIIa(CD16a)和FcγRIII/b(CD16b)。這些受體與IgG抗體的Fc部分結合。CD16由兩個不同的高度同源基因以細胞類型特異的方式編碼。CD16存在于自然殺傷細胞、中性粒細胞、多形核白細胞、單核細胞和巨噬細胞的表面。
CD16a抗原也稱為低親和力免疫球蛋白γFc區(qū)受體III-A、FcγRIIIα。CD16b是一種低親和力的GPI連接受體,由中性粒細胞和嗜酸性粒細胞表達,而CD16a是一種中等親和力的多肽錨定跨膜糖蛋白,由自然殺傷細胞、巨噬細胞、T細胞亞群、未成熟胸腺細胞和胎盤滋養(yǎng)層細胞表達。CD16a參與吞噬作用、酶和炎癥介質(zhì)的分泌、抗體依賴性細胞毒性和免疫復合物的清除。CD16a的異常表達或突變與復發(fā)性病毒感染、系統(tǒng)性紅斑狼瘡和同種免疫新生兒中性粒細胞減少癥的易感性有關。
關鍵字: FCGR3;FCGR3蛋白;CD16重組蛋白;ACRO;百普賽斯;
百普賽斯集團ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國生物科技公司,是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領域提供關鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團業(yè)務遍布全球,橫跨亞洲、北美洲、歐洲,在中國、美國、瑞士等12個城市設有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計服務客戶超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關系。集團旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學等。